Q3 EPS Estimate for Mind Medicine (MindMed) Cut by Analyst

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimate for Mind Medicine (MindMed) to ($0.51) per share, down from a previous estimate of ($0.36).
• The company reported a Q2 EPS of ($0.50), which missed analyst expectations by ($0.12).
• Despite the negative outlook, seven analysts maintain a "buy" rating for Mind Medicine (MindMed) with an average price target of $24.71.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for Mind Medicine (MindMed) in a research note issued to investors on Monday, August 4th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.51) for the quarter, down from their prior estimate of ($0.36). The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)'s Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.78) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.04) EPS and FY2027 earnings at ($1.48) EPS.

Other research analysts have also recently issued reports about the company. Oppenheimer started coverage on Mind Medicine (MindMed) in a research note on Monday, August 4th. They issued an "outperform" rating and a $25.00 price objective for the company. Chardan Capital restated a "buy" rating and issued a $20.00 price objective on shares of Mind Medicine (MindMed) in a research note on Friday, August 1st. Finally, Cantor Fitzgerald upgraded Mind Medicine (MindMed) to a "strong-buy" rating in a research note on Tuesday, May 13th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $24.71.

Mind Medicine (MindMed) Stock Performance

Shares of NASDAQ:MNMD traded down $0.14 during trading on Wednesday, hitting $9.85. The stock had a trading volume of 1,184,575 shares, compared to its average volume of 1,271,573. Mind Medicine has a 12-month low of $4.70 and a 12-month high of $10.44. The stock has a market capitalization of $744.17 million, a price-to-earnings ratio of -6.44 and a beta of 2.49. The company has a quick ratio of 4.98, a current ratio of 4.98 and a debt-to-equity ratio of 0.22. The stock has a 50-day simple moving average of $8.08 and a two-hundred day simple moving average of $7.21.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.12).

Hedge Funds Weigh In On Mind Medicine (MindMed)

Institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new stake in Mind Medicine (MindMed) in the fourth quarter valued at $111,000. Commonwealth Equity Services LLC raised its position in Mind Medicine (MindMed) by 9.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 21,492 shares of the company's stock valued at $150,000 after purchasing an additional 1,928 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Mind Medicine (MindMed) in the fourth quarter valued at $72,000. LPL Financial LLC raised its position in Mind Medicine (MindMed) by 30.1% in the fourth quarter. LPL Financial LLC now owns 62,334 shares of the company's stock valued at $434,000 after purchasing an additional 14,439 shares during the period. Finally, Corebridge Financial Inc. raised its position in Mind Medicine (MindMed) by 4.1% in the fourth quarter. Corebridge Financial Inc. now owns 40,064 shares of the company's stock valued at $279,000 after purchasing an additional 1,569 shares during the period. Hedge funds and other institutional investors own 27.91% of the company's stock.

Insider Buying and Selling

In related news, CEO Robert Barrow sold 26,491 shares of the firm's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $6.80, for a total transaction of $180,138.80. Following the sale, the chief executive officer directly owned 830,065 shares of the company's stock, valued at $5,644,442. This trade represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Sullivan sold 11,491 shares of the firm's stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $6.80, for a total value of $78,138.80. Following the completion of the sale, the insider directly owned 305,130 shares in the company, valued at approximately $2,074,884. The trade was a 3.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 45,830 shares of company stock valued at $311,644 over the last ninety days. Company insiders own 2.45% of the company's stock.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.